We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Begins Clinical Study on COVID-19 Antiviral Pill
Read MoreHide Full Article
Pfizer (PFE - Free Report) announced initiation of a phase I study on its investigational, novel oral antiviral therapeutic, PF-07321332, to treat COVID-19. The study is being conducted in the United States.
The phase I study is a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety, tolerability and pharmacokinetics of PF-07321332. The phase I study progressed to multiple ascending doses after completing the dosing of single ascending doses in healthy adults.
PF-07321332 is a protease inhibitor designed to prevent viruses from replicating in cells. The candidate has shown anti-viral activity against SARS-CoV-2, the virus that causes COVID-19, as well as activity against other coronaviruses in in-vitro studies conducted to date. This means it has the potential to be used for treating COVID-19.
Pfizer’s stock has declined 3.9% so far this year compared with 0.2% decrease for the industry.
Pfizer has designed the oral candidate in such a way that it can be given at the first sign of infection without the patient requiring hospitalization or critical. Most medicines that have received emergency approval for treating COVID-19 can usually be prescribed to treat hospitalized patients or those with severe infection or patients at high risk for progressing to severe COVID-19.
Meanwhile. Pfizer’s intravenous antiviral protease inhibitor, PF-07304814, is being evaluated in a phase Ib multi-dose study as a treatment option for hospitalized COVID-19 patients.
Merck (MRK - Free Report) is also evaluating an oral antiviral candidate, molnupiravir in a mid-stage study for treating COVID-19 in partnership with Ridgeback Biotherapeutics.
Antiviral drugs can prove to be another type of therapy to treat COVID-19 along with antibody drugs approved by the FDA. Lilly’s (LLY - Free Report) antibody drug, bamlanivimab alone and in combination with etesevimab and Regeneron’s (REGN - Free Report) antibody cocktail, REGEN-COV (casirivimab with imdevimab) are approved for emergency use by the FDA for treating COVID-19.
Pfizer and its Germany-based partner BioNTech have successfully developed a two-shot vaccine, BNT162b2, for COVID-19 in record time, which is now approved for emergency/temporary use in more than 50 countries worldwide.
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Image: Bigstock
Pfizer (PFE) Begins Clinical Study on COVID-19 Antiviral Pill
Pfizer (PFE - Free Report) announced initiation of a phase I study on its investigational, novel oral antiviral therapeutic, PF-07321332, to treat COVID-19. The study is being conducted in the United States.
The phase I study is a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety, tolerability and pharmacokinetics of PF-07321332. The phase I study progressed to multiple ascending doses after completing the dosing of single ascending doses in healthy adults.
PF-07321332 is a protease inhibitor designed to prevent viruses from replicating in cells. The candidate has shown anti-viral activity against SARS-CoV-2, the virus that causes COVID-19, as well as activity against other coronaviruses in in-vitro studies conducted to date. This means it has the potential to be used for treating COVID-19.
Pfizer’s stock has declined 3.9% so far this year compared with 0.2% decrease for the industry.
Pfizer has designed the oral candidate in such a way that it can be given at the first sign of infection without the patient requiring hospitalization or critical. Most medicines that have received emergency approval for treating COVID-19 can usually be prescribed to treat hospitalized patients or those with severe infection or patients at high risk for progressing to severe COVID-19.
Meanwhile. Pfizer’s intravenous antiviral protease inhibitor, PF-07304814, is being evaluated in a phase Ib multi-dose study as a treatment option for hospitalized COVID-19 patients.
Merck (MRK - Free Report) is also evaluating an oral antiviral candidate, molnupiravir in a mid-stage study for treating COVID-19 in partnership with Ridgeback Biotherapeutics.
Antiviral drugs can prove to be another type of therapy to treat COVID-19 along with antibody drugs approved by the FDA. Lilly’s (LLY - Free Report) antibody drug, bamlanivimab alone and in combination with etesevimab and Regeneron’s (REGN - Free Report) antibody cocktail, REGEN-COV (casirivimab with imdevimab) are approved for emergency use by the FDA for treating COVID-19.
Pfizer and its Germany-based partner BioNTech have successfully developed a two-shot vaccine, BNT162b2, for COVID-19 in record time, which is now approved for emergency/temporary use in more than 50 countries worldwide.
Pfizer currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>